The leadership of Sage Bionetworks concludes Commons Congress 2013 with a closing panel.
Dr. Ford-Hutchinson is Senior Vice President, Vaccines Research and Development Merck Research Laboratories. He has a 30 year record of success at Merck & Co., Inc. and was Senior Vice President and Site Head of Merck Frosst Canada during the development of SingulairÂ® for the treatment of adult and pediatric asthma and allergic rhinitis and the discovery of selective COX-2 inhibitors for the treatment of osteoarthritis and pain. Before joining Merck he was a lecturer in the Chemical Pathology Department at Kings College Hospital Medical School in London doing leukotriene and prostaglandin research. Dr. Ford-Hutchinson obtained his Bachelorâ€™s Degree in Biochemistry from the University of Birmingham, a Masters Degree in Molecular Enzymology from the University of Warwick, and a Ph.D. in Biochemistry from the University of London.
Jeff Hammerbacher is a founder and the Chief Scientist of Cloudera. Hammerbacher was an Entrepreneur in Residence at Accel Partners immediately prior to founding Cloudera. Before Accel, he conceived, built, and led the Data team at Facebook. The Data team was responsible for driving many of the applications of statistics and machine learning at Facebook, as well as building out the infrastructure to support these tasks for massive data sets. The Data team produced open source projects such as Hive and Cassandra and their work was recognized at conferences such as CHI, ICWSM, SIGMOD, and VLDB. Before joining Facebook, Hammerbacher was a quantitative analyst on Wall Street. Hammerbacher earned his Bachelor's Degree in Mathematics from Harvard University and recently served as a Contributing Editor for O'Reilly's "Beautiful Data".
Eric Schadt, PhD, is Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences, and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai. Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. He has published more than 200 peer-reviewed papers in leading scientific journals, and contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Dr. Schadt is also a founding member of Sage Bionetworks, an open-access genomics initiative designed to build and support databases and an accessible platform for creating innovative dynamic disease models. Prior to joining Mount Sinai in 2011, he was Chief Scientific Officer at Pacific Biosciences, the next-generation sequencing technology provider. Previously, Dr. Schadt was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. in Seattle, and before Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics from University of California, Davis, and his Ph.D. in bio-mathematics from University of California, Los Angeles (requiring Ph.D. candidacy in molecular biology and mathematics).
Gustavo Stolovitzky received his M.Sc. in Physics (with honors) from the University of Buenos Aires, Argentina (1987) and his Ph.D. in Mechanical Engineering from Yale University (1994), which awarded him the Henry Prentiss Becton Prize for Excellence in Engineering and Applied Sciences. After a post-doctoral position in the Center for Studies in Physics and Biology at The Rockefeller University, he joined IBM Research in 1998, where he is a research staff member in the IBM Computational Biology Center and the manager of the IBM Functional Genomics and Systems Biology Group. He holds an adjunct Associate Professor position at Columbia University.
As VP of Science, John Wilbanks runs the Science Commons project at Creative Commons. He came to Creative Commons from a Fellowship at the World Wide Web Consortium in Semantic Web for Life Sciences. Previously, he founded and led to acquisition Incellico, a bioinformatics company that built semantic graph networks for use in pharmaceutical research & development. Previously, John was the first Assistant Director at the Berkman Center for Internet and Society at Harvard Law School and also worked in US politics as a legislative aide to U.S. Representative Fortney (Pete) Stark.
John holds a Bachelor of Arts in Philosophy from Tulane University and studied modern letters at the Universite de Paris IV (La Sorbonne). He was a research affiliate at the MIT Computer Science and Artificial Intelligence Laboratory in the project on Mathematics and Computation. John also serves on the Advisory Boards of the U.S. National Library of Medicine’s PubMed Central, the Open Knowledge Foundation, the Open Knowledge Definition, and the International Advisory Board of the Prix Ars Electronica’s Digital Communities awards. He also serves on the Board of Directors of the Fedora Commons digital repository organization.